The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
These distinguished individuals have been pivotal in shaping the direction of NETRF’s scientific programs. Dr. Shivdasani led as BOSA Chair from 2007 to 2016, followed by Drs. Fisher and Chung, who co-chaired from 2016 to 2022. Their expertise, leadership, and unwavering commitment have been instrumental in advancing our mission to accelerate research and improve outcomes for those affected by neuroendocrine cancer.
As they step down from their roles on the BOSA, we are pleased to announce that Drs. Shivdasani, Fisher, and Chung will transition to BOSA Emeritus status. This transition recognizes the excellence they have brought to the Foundation, and we are privileged to continue benefiting from their wisdom and experience in this new capacity.
We express our heartfelt thanks to Drs. Shivdasani, Fisher, and Chung for their dedication and profound impact on our community. Under their leadership, NETRF has become the leading global funder of neuroendocrine cancer research, supporting innovative research that has significantly advanced our understanding of this disease.